These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16926623)

  • 1. Importance of p53 for cancer onset and therapy.
    Haupt S; Haupt Y
    Anticancer Drugs; 2006 Aug; 17(7):725-32. PubMed ID: 16926623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
    Bossi G; Sacchi A
    Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2.
    Tachibana M; Kawamata H; Fujimori T; Omotehara F; Horiuchi H; Ohkura Y; Igarashi S; Kotake K; Kubota K
    Int J Oncol; 2004 Oct; 25(4):913-20. PubMed ID: 15375540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods for screening tumors for p53 status and therapeutic exploitation.
    Tullo A; D'Erchia AM; Sbisà E
    Expert Rev Mol Diagn; 2003 May; 3(3):289-301. PubMed ID: 12779005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression.
    Meng RD; Shih H; Prabhu NS; George DL; el-Deiry WS
    Clin Cancer Res; 1998 Jan; 4(1):251-9. PubMed ID: 9516979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.
    Hernandez I; Maddison LA; Wei Y; DeMayo F; Petras T; Li B; Gingrich JR; Rosen JM; Greenberg NM
    Mol Cancer Res; 2003 Dec; 1(14):1036-47. PubMed ID: 14707287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The tumor supressor gene p53].
    Stríteská D
    Acta Medica (Hradec Kralove) Suppl; 2005; 48(1):21-5. PubMed ID: 16669487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
    Chène P
    Nat Rev Cancer; 2003 Feb; 3(2):102-9. PubMed ID: 12563309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of p14ARF overcomes tumor resistance to p53.
    Lu W; Lin J; Chen J
    Cancer Res; 2002 Mar; 62(5):1305-10. PubMed ID: 11888896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress of p53 gene].
    Xu SF; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):559-61. PubMed ID: 15634457
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities.
    Hong B; van den Heuvel AP; Prabhu VV; Zhang S; El-Deiry WS
    Curr Drug Targets; 2014 Jan; 15(1):80-9. PubMed ID: 24387333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The p53 mutation "gradient effect" and its clinical implications.
    Zambetti GP
    J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates on p53: modulation of p53 degradation as a therapeutic approach.
    Dey A; Verma CS; Lane DP
    Br J Cancer; 2008 Jan; 98(1):4-8. PubMed ID: 18182973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic exploitation of the p53 pathway.
    Lane DP; Lain S
    Trends Mol Med; 2002; 8(4 Suppl):S38-42. PubMed ID: 11927286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.
    Harris CC
    J Natl Cancer Inst; 1996 Oct; 88(20):1442-55. PubMed ID: 8841019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells.
    Bull EK; Chakrabarty S; Brodsky I; Haines DS
    Oncogene; 1998 Apr; 16(17):2249-57. PubMed ID: 9619834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 and mdm-2: interactions between tumor suppressor gene and oncogene products.
    Perry ME; Levine AJ
    Mt Sinai J Med; 1994 Sep; 61(4):291-9. PubMed ID: 7969222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achilles' heel of cancer?
    Vogelstein B; Kinzler KW
    Nature; 2001 Aug; 412(6850):865-6. PubMed ID: 11528457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.